Evidence map›Paper›PMID 38534327›Full record

ArticleCells2024

Isolevuglandins Promote Mitochondrial Dysfunction and Electrophysiologic Abnormalities in Atrial Cardiomyocytes.

Tuerdi Subati, Zhenjiang Yang, Matthew B Murphy, Joshua M Stark, David Z Trykall, Sean S Davies, Joey V Barnett, Katherine T Murray

Open access · goldAbstract read
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Tuerdi SubatiDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Zhenjiang YangDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-9315-154X
Matthew B MurphyDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Joshua M StarkDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
David Z TrykallDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.ORCID 0000-0002-9132-7855
Sean S DaviesDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Joey V BarnettDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Katherine T MurrayDepartments of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232, USA.
Vanderbilt University · US

Funding

Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STACIE B DUSETZINA · 1995 to 2026
$172.8M
Translational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9M
Vanderbilt Diabetes Research CenterP30DK020593 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI ALVIN C POWERS · 2012 to 2026
$29.3M
Non-coding RNA & Bioinformatics CoreP01HL116263 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LINTON, MACRAE F · 2014 to 2025
$24.7M
Shop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI David J. Calkins · 1989 to 2026
$19.6M
Vanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9M
Novel Pathophysiological Targets in Atrial Fibrillation SusceptibilityR01HL133127 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MURRAY, KATHERINE T · 2017 to 2020
$2.1M
Preamyloid Oligomers and Susceptibility to Atrial FibrillationR01HL096844 · NHLBI · VANDERBILT UNIVERSITY · PI MURRAY, KATHERINE T · 2010 to 2014
$1.9M
XFe96 AnalyzerS10OD018015 · OD · VANDERBILT UNIVERSITY · PI LANNIGAN, DEBORAH · 2014 to 2014
$200k
NCI NIH HHS P30 CA068485NEI NIH HHS P30 EY008126NHLBI NIH HHS P01 HL116263NHLBI NIH HHS R01 HL096844NHLBI NIH HHS R01 HL133127NIDDK NIH HHS P30 DK020593NIDDK NIH HHS P30 DK058404NIDDK NIH HHS U24 DK059637NIH HHS S10 OD018015
6 · The paper itself

Abstract

Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, yet the cellular and molecular mechanisms underlying the AF substrate remain unclear. Isolevuglandins (IsoLGs) are highly reactive lipid dicarbonyl products that mediate oxidative stress-related injury. In murine hypertension, the lipid dicarbonyl scavenger 2-hydroxybenzylamine (2-HOBA) reduced IsoLGs and AF susceptibility. We hypothesized that IsoLGs mediate detrimental pathophysiologic effects in atrial cardiomyocytes that promote the AF substrate. Using Seahorse XFp extracellular flux analysis and a luminescence assay, IsoLG exposure suppressed intracellular ATP production in atrial HL-1 cardiomyocytes. IsoLGs caused mitochondrial dysfunction, with reduced mitochondrial membrane potential, increased mitochondrial reactive oxygen species (ROS) with protein carbonylation, and mitochondrial DNA damage. Moreover, they generated cytosolic preamyloid oligomers previously shown to cause similar detrimental effects in atrial cells. In mouse atrial and HL-1 cells, patch clamp experiments demonstrated that IsoLGs rapidly altered action potentials (AP), implying a direct effect independent of oligomer formation by reducing the maximum Phase 0 upstroke slope and shortening AP duration due to ionic current modifications. IsoLG-mediated mitochondrial and electrophysiologic abnormalities were blunted or totally prevented by 2-HOBA. These findings identify IsoLGs as novel mediators of oxidative stress-dependent atrial pathophysiology and support the investigation of dicarbonyl scavengers as a novel therapeutic approach to prevent AF.

Indexed as

Atrial FibrillationBenzylaminesMitochondrial DiseasesAnimalsLipidsMiceMyocytes, CardiacReactive Oxygen Species2-(aminomethyl)phenolBenzylaminesisolevuglandinLipidsReactive Oxygen Speciesatrial fibrillationatrial HL-1 cellselectrophysiologyIsolevuglandinslipid dicarbonylmitochondriaoxidative stress

Identifiers

PMID38534327
PMCPMC10969716
OpenAlexW4392649541

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.